Alison Oliver

Senior Medical Information Scientist UKTIS (NHS/UKHSA). Med safety in pregnancy & women’s health. MCL.

[Alison Oliver @drAlisonOliver]

This is great news for our family and others affected by MCL. I am still disappointed that the treatment could not be appraised via the HST route as it is an ultra rare cancer. But this is a step in the right direction!

[Anthony Nolan @AnthonyNolan]

In December, NICE published final guidance recommending the removal of Tecartus for patients with relapsed or refractory mantle cell lymphoma from the NHS.
We submitted a joint appeal with @bloodcancer_uk and @LymphomaAction and today NICE announced they will reconsider.

[Alison Oliver @drAlisonOliver]

@JJFarrell451 Sorry for your loss.. My husband is a firefighter and also diagnosed with mantle cell lymphoma.

[Alison Oliver @drAlisonOliver]

@NICEComms People with rare lymphomas also deserve access to CAR-T https://t.co/Fu4iuryNlB

[Alison Oliver @drAlisonOliver]

@NICEComms This is brilliant, but what about people with rare lymphomas like mantle cell lymphoma? The only CAR-T option available in that case has not been recommended in the latest review. When can we expect the result of the appeal?

[Toby Eyre @tobyeyre82]

▶️▶️Happy to share this now live. Everything new in #MCL in the @ASCO Ed Book 2026 #MCL #lymsm

Modern Management of Mantle Cell Lymphoma | American Society of Clinical Oncology Educational Book https://t.co/STrUcjOIfq

[Alison Oliver @drAlisonOliver]

@William45259616 @GingerWildheart @TheWildhearts We live not far from where he hales from. Treated at the freeman in Newcastle.

[Alison Oliver @drAlisonOliver]

@William45259616 @GingerWildheart @TheWildhearts My husband also has MCL, diagnosed 2024 with aggressive disease (would def not have survived more than a couple of days without surgical intervention as he had blockage in colon). He’s now in remission after treatment and back firefighting. He had intensive chemo.

[Alison Oliver @drAlisonOliver]

@LymphomaAction @AnthonyNolan @bloodcancer_uk https://t.co/3FZ7rMvZM7

[Alison Oliver @drAlisonOliver]

https://t.co/Fu4iurzlb9

[Alison Oliver @drAlisonOliver]

@AnthonyNolan @LymphomaAction @bloodcancer_uk @wesstreeting https://t.co/3FZ7rMvZM7

[Alison Oliver @drAlisonOliver]

https://t.co/Fu4iurzlb9

[LymphomaAction @LymphomaAction]

We're proud to be continuing to work alongside @AnthonyNolan and @BloodCancer_UK on this important issue. #Tecartus

[Alison Oliver @drAlisonOliver]

https://t.co/Fu4iurzlb9

[Alison Oliver @drAlisonOliver]

@wesstreeting

[Alison Oliver @drAlisonOliver]

Having a rare cancer feels like an uphill struggle. Evidence for treatments is painfully slow to accumulate and then they are often too expensive to access. This makes us a global outlier however: https://t.co/NN5aAxn9lJ

[Alison Oliver @drAlisonOliver]

@JANEDART5 @AnthonyNolan It looks to be selected for appraisal by NICE but it’s likely to go the same way as brexu-cel if the same QALY threshold is used.

[Alison Oliver @drAlisonOliver]

@michaelwangmd How can we expedite the development of this for MCL? We appear to be losing car-t in the UK and until something which is more cost effective is available, we effectively have no 3rd line option for durable remission. A very worrying situation @NICEComms

[Alison Oliver @drAlisonOliver]

@AnthonyNolan My husband has MCL at only 42 and it feels like the removal of a line of treatment and the removal of a safety net. I know of another younger MCL patient who has needed to use car-t as a bridge to allo SCT.

[Anthony Nolan @AnthonyNolan]

Brexu-cel is a game changer that has significantly improved survival for what was previously an incurable blood cancer. It is the only CAR-T option available for people with MCL. It is very troubling that this lifeline is now being removed, taking NHS care backwards.

[Alison Oliver @drAlisonOliver]

This is really awful news. Options are now even more limited for MCL in the UK. What happens when the BTK inhibitor stops working? @NICEComms

[Anthony Nolan @AnthonyNolan]

We are deeply concerned at the decision by NICE to remove the CAR-T treatment Tecartus (brexu-cel) for Mantle Cell Lymphoma (MCL)  after 4 years of it being available on the NHS in England and Wales.

[Alison Oliver @drAlisonOliver]

@tobyeyre82 Is it likely that the BOVen regimen will be available for patients with TP53 mutation in the UK? And what do you think the timeline for that would be? Seems like this particular group of MCL patients are not being treated optimally in the first line.